

Supplementary Table S1. Overview of unadjusted median and low (<0.5 µg/l) anti-Müllerian hormone (AMH) levels during treatment for childhood classical Hodgkin lymphoma and AMH recovery after 2 years.

AMH (µg/l)	Treatment level											
	N	All patients* Median (IQR)	TL1		TL2		TL3		TL2/3 COPDAC-28 arm		TL2/3 DECOPDAC-21 arm	
			N	Median (IQR)	N	Median (IQR)	N	Median (IQR)	N	Median (IQR)	N	Median (IQR)
T0: at diagnosis	97	1.7 [0.9; 2.7]	18	1.9 [1.2; 2.9]	44	1.8 [1.0; 2.7]	35	1.5 [0.7; 2.6]	51	1.6 [0.7; 2.5]	28	1.8 [1.0; 3.2]
T1: after 2× OEPA	100	0.06 [0.03; 0.1]	18	0.07 [0.03; 0.18]	46	0.05 [0.03; 0.1]	36	0.06 [0.03; 0.1]	54	0.06 [0.03; 0.1]	28	0.06 [0.03; 0.2]
T1b: after 1× COPDAC	15	0.7 [0.3; 1.4]	15	0.7 [0.3; 1.4]	0	—	0	—	0	—	0	—
T2: after 2× (DE)COPDAC	76	0.4 [0.1; 1.0]	0	—	44	0.5 [0.2; 1.0]	32	0.2 [0.06; 0.8]	50	0.6 [0.2; 1.7]	26	0.1 [0.04; 0.3]
T3: after 4× (DE)COPDAC	29	0.5 [0.08; 2.1]	0	—	0	—	29	0.5 [0.08; 2.1]	17	0.9 [0.4; 3.0]	12	0.08 [0.03; 0.6]
T4: 2 years post-diagnosis	73	2.1 [1.0; 3.8]	15	2.8 [1.5; 4.3]	38	2.3 [1.1; 4.1]	20	1.3 [0.8; 2.1]	36	2.1 [0.9; 3.8]	22	1.8 [0.9; 3.7]
T5: 5 years post-diagnosis or age 18 years old.	12	3.9 [2.1; 7.9]	2	6.5 [4.2; 8.8]	9	3.8 [1.5; 7.3]	1	2.8	5	4.0 [1.9; 9.8]	5	2.2 [1.2; 4.6]
AMH <0.5 µg/l	N	n (%)	N	n (%)	N	n (%)	N	n (%)	N	n (%)	N	n (%)
T0: at diagnosis	97	12 (12%)	18	1 (6%)	44	6 (14%)	35	5 (14%)	51	9 (18%)	28	2 (7%)
T1: after 2× OEPA	100	98 (98%)	18	18 (100%)	46	45 (98%)	36	35 (97%)	54	52 (96%)	28	28 (100%)
T1b: after 1× COPDAC	15	7 (47%)	15	7 (47%)	0	—	0	—	0	—	0	—
T2: after 2× (DE)COPDAC	76	42 (55%)	0	—	44	21 (48%)	32	21 (66%)	50	20 (40%)	26	22 (85%)
T3: after 4× (DE)COPDAC	29	15 (52%)	0	—	0	—	29	15 (52%)	17	6 (35%)	12	9 (75%)
T4: 2 years post-diagnosis	73	5 (7%)	15	0 (0%)	38	2 (5%)	20	3 (15%)	36	3 (8%)	22	2 (9%)
T5: 5 years post-diagnosis or age 18 years old.	12	1 (8%)	2	0 (0%)	9	1 (11%)	1	0 (0%)	5	0 (0%)	5	1 (20%)
AMH recovery compared to baseline	N	n (%)	N	n (%)	N	n (%)	N	n (%)	N	n (%)	N	n (%)
Reached baseline value	68	46 (68%)	15	12 (80%)	33	24 (73%)	20	10 (50%)	31	23 (74%)	22	11 (50%)

TL, treatment level; OEPA, vincristine, etoposide, prednisone, doxorubicin; COPDAC-28, cyclophosphamide, vincristine, prednisone and dacarbazine; DECOPDAC-21, doxorubicin, etoposide, cyclophosphamide, vincristine, prednisone and dacarbazine; N group total, n, number. Assigned treatment was according to the EuroNet-PHL-C2 protocol (see treatment-flow in [Supplementary Fig. S1](#)). TL1 patients receive 2× OEPA induction followed by either 1× COPDAC-28 or involved field radiotherapy. TL2/TL3 patients are randomized between the COPDAC-28 and DECOPDAC-21 treatment schemes and receive 2× OEPA induction followed by 2× (TL2) or 4× (TL3) (DE)COPDAC consolidation. Indication for radiotherapy depends on treatment response and treatment-group.

* Samples drawn in patients after receiving pelvic radiotherapy (n = 4 T4 and n = 1 T5 samples) were excluded from the analyses. Recovery was assessed in cases where both T0 and T4 samples were available.